New drug duo aims to shrink tough liver tumors
NCT ID NCT05194293
Summary
This study is testing if a combination of two drugs, regorafenib and durvalumab, can shrink tumors in adults with high-risk liver cancer. The goal is to see if this treatment makes surgery more effective or possible. Patients receive the drugs for up to two years and are then monitored to see how long the cancer stays under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
Conditions
Explore the condition pages connected to this study.